Exploring actionable targets to address disparities in thyroid cancer survival: A study of patients with aggressive variants of papillary thyroid cancer.
1/5 보강
[BACKGROUND] Despite compromised survival, disparities studies on aggressive variants of papillary thyroid cancer (PTC) are sparse.
APA
Monreal AJ, Eze AN, et al. (2025). Exploring actionable targets to address disparities in thyroid cancer survival: A study of patients with aggressive variants of papillary thyroid cancer.. American journal of surgery, 248, 116428. https://doi.org/10.1016/j.amjsurg.2025.116428
MLA
Monreal AJ, et al.. "Exploring actionable targets to address disparities in thyroid cancer survival: A study of patients with aggressive variants of papillary thyroid cancer.." American journal of surgery, vol. 248, 2025, pp. 116428.
PMID
40435539 ↗
Abstract 한글 요약
[BACKGROUND] Despite compromised survival, disparities studies on aggressive variants of papillary thyroid cancer (PTC) are sparse.
[METHODS] Using the NCDB (2004-20), adult Non-Hispanic Whites (NHW), Non-Hispanic Asians or Pacific Islanders (NHAPI), Hispanics, and Non-Hispanic Blacks (NHB) with aggressive variants were abstracted. Mortality risk was estimated using Hazard Ratios (HR).
[RESULTS] NHB patients had larger tumors (p < 0.001) but lower thyroidectomy rates (p = 0.04). For all patients, cancer stage posed the strongest mortality risk (HRs Stage II-IV vs. Stage I: 2.75, 4.18, 8.04, p < 0.001), however, this was substantially higher by stage for NHBs (HRs Stage II-IV: 4.78, 7.57, 10.49, p < 0.001). Age ≥55 years was the strongest risk factor for Hispanics (p < 0.001); non-private insurance was the strongest risk factor for NHAPI, NHBs, and NHWs.
[CONCLUSION] Beyond health insurance, actionable targets to improve PTC survival vary by race/ethnicity. For NHBs, higher clinical stage and worse survival by stage might indicate compromised access to optimal care. For Hispanics, improved follow-up, particularly for patients ≥55 years, may enhance survival.
[METHODS] Using the NCDB (2004-20), adult Non-Hispanic Whites (NHW), Non-Hispanic Asians or Pacific Islanders (NHAPI), Hispanics, and Non-Hispanic Blacks (NHB) with aggressive variants were abstracted. Mortality risk was estimated using Hazard Ratios (HR).
[RESULTS] NHB patients had larger tumors (p < 0.001) but lower thyroidectomy rates (p = 0.04). For all patients, cancer stage posed the strongest mortality risk (HRs Stage II-IV vs. Stage I: 2.75, 4.18, 8.04, p < 0.001), however, this was substantially higher by stage for NHBs (HRs Stage II-IV: 4.78, 7.57, 10.49, p < 0.001). Age ≥55 years was the strongest risk factor for Hispanics (p < 0.001); non-private insurance was the strongest risk factor for NHAPI, NHBs, and NHWs.
[CONCLUSION] Beyond health insurance, actionable targets to improve PTC survival vary by race/ethnicity. For NHBs, higher clinical stage and worse survival by stage might indicate compromised access to optimal care. For Hispanics, improved follow-up, particularly for patients ≥55 years, may enhance survival.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Thyroid Neoplasms
- Female
- Male
- Middle Aged
- Thyroid Cancer
- Papillary
- Adult
- Thyroidectomy
- Aged
- United States
- Healthcare Disparities
- Neoplasm Staging
- Survival Rate
- Health Status Disparities
- Risk Factors
- Carcinoma
- Aggressive variants
- Endocrine surgery
- Ethnicity
- Papillary thyroid cancer
- Race
- Survival
- Thyroid cancer
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.